KEVIN CARNEY: Open Payments
NPI 1871874685 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,746 in 60 payments from 12 companies in 2025. Trend: 2023 $14,053 · 2024 $8,800 · 2025 $8,746
Honoraria: $3,610Speaker / faculty: $2,374Food & beverage: $2,102Travel & lodging: $660
| Company | Payments | Amount |
|---|---|---|
| Verona Pharma, Inc. | 19 | $7,309 |
| AstraZeneca Pharmaceuticals LP | 8 | $441 |
| Viatris Specialty LLC | 11 | $301 |
| GlaxoSmithKline, LLC. | 9 | $233 |
| Astellas Pharma US Inc | 3 | $185 |
| Pulmonx Corporation | 3 | $101 |
| Amgen Inc. | 2 | $52 |
| United Therapeutics Corporation | 1 | $37 |
| AtriCure, Inc. | 1 | $27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
Products named: Ohtuvayre, YUPELRI, NUCALA, Cresemba, BREZTRI, FASENRA, CHARTIS CATHETER, TEZSPIRE.
Industry payments across PA — which companies pay providers there.
